Combination with SN-38 on human colon cancer LoVo cells / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 746-851, 2009.
Artículo
en Chino
| WPRIM
| ID: wpr-293061
ABSTRACT
<p><b>OBJECTIVE</b>To observe the anti-proliferation effect of bevacizumab and SN-38 (active metabolite of irinotecan), and investigate the possible mechanisms of these two agents.</p><p><b>METHODS</b>Human colon cancer LoVo cells were cultured under hypoxic conditions. Inhibition of cell proliferation was evaluated by MTT assay. The drug modulation on HIF-1alpha, VEGF, ERK and AKT were assessed by the following assays. The mRNA expression of HIF-1alpha and VEGF were measured by RT-PCR. The protein expression of HIF-1alpha, ERK and AKT were evaluated by Western blot analysis, and VEGF by ELISA assay.</p><p><b>RESULTS</b>Among different combination schedules, Bevacizumab given after SN-38 show most synergistic anti-proliferation effect. Under hypoxic conditions, the expression of HIF-1alpha and VEGF increased as time accumulated, Bevacizumab combined with SN-38 almost completely inhibited the expression of HIF-1alpha and VEGF. Moreover, the MAP kinase pathway was involved in the drug modulation of HIF-1alpha and VEGF.</p><p><b>CONCLUSION</b>These findings suggest the anti-proliferation effect of bevacizumab and SN-38 was schedule-dependent, and the synergistic effect of Bevacizumab and SN-38 was related to drug modulation of the HIF-1alpha and MAP kinase pathway.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Farmacología
/
Factores de Tiempo
/
Camptotecina
/
ARN Mensajero
/
Transducción de Señal
/
Hipoxia de la Célula
/
Neoplasias del Colon
/
Línea Celular Tumoral
/
Factor A de Crecimiento Endotelial Vascular
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS